Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1582-1590

  Stathis, Anastasios ^a   Hotte, Sebastien J ^a   Chen, Eric X ^a   Hirte, Holger W ^a   Oza, Amit M ^a   Moretto, Patricia ^a   Webster, Sheila ^a   Laughlin, Anne ^a   Stayner, Lee Anne ^a   McGill, Shauna ^a   Wang, Lisa ^a   Zhang, Wen Jiang ^a   Espinoza Delgado, Igor ^b   Holleran, Julianne L ^c   Egorin, Merrill J ^c   Siu, Lillian L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PREDNISONE; VORINOSTAT;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CONTROL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPONATREMIA; HYPOTENSION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROMOTER REGIONS, GENETIC; TIME FACTORS;

EID: 79952710830     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1893     Document Type: Article

References (30)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
3. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009;15:3918-26.
4. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-20-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 1983;43:3493-6. (Pubitemid 13026595)
5. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-93. (Pubitemid 29436325)
6. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803.
7. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247-52. (Pubitemid 350106355)
8. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
9. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009;15:3938-46.
10. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 1999;21:103-7. (Pubitemid 29036293)
11. Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 2002;21:2741-9. (Pubitemid 34478332)
12. Boivin AJ, Momparler LF, Hurtubise A, Momparler RL. Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 2002;13:869-74.
13. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61:1327-33. (Pubitemid 34292551)
14. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29:739-48. (Pubitemid 40779480)
15. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109:265-73. (Pubitemid 46106241)
16. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31. (Pubitemid 46218695)
17. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-6.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006;20:1117-26.
20. Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2006;840:108-15. (Pubitemid 44163473)
21. Alencar C, Abramowtiz M, Parekh S, Braunshweig I, Jacobson M, Silverman L, et al. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol 2009;84:688-9.
22. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-91. (Pubitemid 47477265)
23. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-7.
24. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′- deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9.
25. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9.
26. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008;14:6296-301.
27. Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 2009;15:6241-9.
28. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008;14:7138-42.
29. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:56-62.
30. Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, et al. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 2010;16:3786-94.